Mera Pharmaceuticals Inc
Mera Pharmaceuticals, Inc. focuses on the development and commercialization of natural products from microalgae using its proprietary and large-scale photobioreactor technology. The company is also involved in the development of sea salt; and operation of family entertainment center focused on promoting health and wellness through the Villari's system of martial arts. In addition, it provides foo… Read more
Mera Pharmaceuticals Inc (MRPI) - Net Assets
Latest net assets as of July 2021: $-38.65K USD
Based on the latest financial reports, Mera Pharmaceuticals Inc (MRPI) has net assets worth $-38.65K USD as of July 2021.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($0.00) and total liabilities ($38.65K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-38.65K |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | -147.66% |
| 10-Year Change | -234.81% |
| Growth Volatility | 136.99 |
Mera Pharmaceuticals Inc - Net Assets Trend (1996–2011)
This chart illustrates how Mera Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Mera Pharmaceuticals Inc (1996–2011)
The table below shows the annual net assets of Mera Pharmaceuticals Inc from 1996 to 2011.
| Year | Net Assets | Change |
|---|---|---|
| 2011-10-31 | $-864.62K | -27.72% |
| 2010-10-31 | $-676.94K | -386.65% |
| 2009-10-31 | $-139.10K | -358.67% |
| 2008-10-31 | $53.78K | -97.04% |
| 2007-10-31 | $1.81 Million | -9.07% |
| 2006-10-31 | $2.00 Million | -10.76% |
| 2005-10-31 | $2.24 Million | -23.96% |
| 2004-10-31 | $2.94 Million | +48.31% |
| 2003-10-31 | $1.98 Million | +209.12% |
| 2002-10-31 | $641.38K | +240.06% |
| 2001-10-31 | $-457.95K | -176.62% |
| 2000-10-31 | $597.67K | +19.53% |
| 1999-10-31 | $500.00K | -53.42% |
| 1998-10-31 | $1.07 Million | +1107.43% |
| 1997-10-31 | $-106.55K | -136.64% |
| 1996-10-31 | $290.80K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Mera Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 294025600.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (October 2020)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $55.73 | % |
| Other Components | $8.38K | % |
| Total Equity | $-29.76 | 100.00% |
Mera Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Mera Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Equal Trading Inc
PINK:EQTD
|
$1.00 |
|
Foy Johnston Inc
PINK:FOYJ
|
$1.00 |
|
Alliance Media Holdings Inc
PINK:ADTR
|
$1.00 |
|
WellQuest Medical & Wellness Corporation
PINK:WEQL
|
$1.00 |
|
Green Cures & Botanical Distribution Inc
PINK:GRCU
|
$1.00 |
|
Global Environmental Energy Corp
PINK:GEECF
|
$1.00 |
|
Flameret Inc
PINK:FLRE
|
$1.00 |
|
International Silver Inc
PINK:ISLV
|
$1.00 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mera Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2011 to 2020, total equity changed from -864,620 to -30, a change of 864,590.
- Net loss of 6 reduced equity.
- Other factors increased equity by 864,596.
Equity Change Factors (2011 to 2020)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.58 | -18.75% |
| Other Changes | $864.60K | +2905227.89% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Mera Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1996-10-31 | $0.01 | $0.00 | x |
| 1997-10-31 | $0.00 | $0.00 | x |
| 1998-10-31 | $0.02 | $0.00 | x |
| 1999-10-31 | $0.01 | $0.00 | x |
| 2000-10-31 | $0.01 | $0.00 | x |
| 2001-10-31 | $0.00 | $0.00 | x |
| 2002-10-31 | $0.00 | $0.00 | x |
| 2003-10-31 | $0.00 | $0.00 | x |
| 2004-10-31 | $0.01 | $0.00 | x |
| 2005-10-31 | $0.00 | $0.00 | x |
| 2006-10-31 | $0.00 | $0.00 | x |
| 2007-10-31 | $0.00 | $0.00 | x |
| 2008-10-31 | $0.00 | $0.00 | x |
| 2009-10-31 | $0.00 | $0.00 | x |
| 2010-10-31 | $0.00 | $0.00 | x |
| 2011-10-31 | $0.00 | $0.00 | x |
| 2020-10-31 | $0.00 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mera Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-366.47%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | -446.34% | -12979.32% | 0.01x | 4.70x | $-1.33 Million |
| 1997 | 0.00% | -172999.35% | 0.00x | 0.00x | $-1.85 Million |
| 1998 | -256.04% | 0.00% | 0.00x | 2.55x | $-2.86 Million |
| 1999 | -820.00% | -4100.00% | 0.03x | 7.20x | $-4.15 Million |
| 2000 | -774.05% | 0.00% | 0.00x | 6.75x | $-4.69 Million |
| 2001 | 0.00% | -396.22% | 0.25x | 0.00x | $-4.05 Million |
| 2002 | -84.49% | -1115.69% | 0.01x | 8.61x | $-606.03K |
| 2003 | -92.35% | -235.91% | 0.18x | 2.15x | $-2.03 Million |
| 2004 | -37.56% | -121.43% | 0.28x | 1.11x | $-1.40 Million |
| 2005 | -58.40% | -336.55% | 0.15x | 1.17x | $-1.53 Million |
| 2006 | -25.48% | -131.45% | 0.16x | 1.22x | $-707.93K |
| 2007 | -17.76% | -68.51% | 0.21x | 1.23x | $-503.68K |
| 2008 | -3617.52% | -318.92% | 1.55x | 7.34x | $-1.95 Million |
| 2009 | 0.00% | -32.20% | 2.33x | 0.00x | $-178.97K |
| 2010 | 0.00% | -186.18% | 3.94x | 0.00x | $-470.14K |
| 2011 | 0.00% | -62.02% | 4.28x | 0.00x | $-101.22K |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.60 |
Industry Comparison
This section compares Mera Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mera Pharmaceuticals Inc (MRPI) | $-38.65K | -446.34% | N/A | $1.00 |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |